ANIPRYL can help to control the clinical signs of canine cognitive dysfunction syndrome (CDS) and PDH
ANIPRYL (selegiline hydrochloride) is indicated for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS) and control of clinical signs associated with uncomplicated canine pituitary dependent hyperadrenocorticism (PDH).
CDS: The recommended dosage for oral administration for the control of clinical signs associated with CDS is 0.5–1.0 mg/kg once daily, preferably administered in the morning. Initially, dogs should be dosed to the nearest whole tablet. Adjustments should then be made based on response and tolerance to the drug.
PDH: The recommended dosage for the control of clinical signs associated with canine PDH is 1.0 mg/kg once daily, preferably administered in the morning. If no improvement is observed after 2 months of therapy, dosage may be increased to a maximum of 2.0 mg/kg once daily. If no improvement is seen after 1 month at the higher dose or if at any time clinical signs progress, the dog should be re-evaluated. In dogs whose clinical signs of PDH progress despite Anipryl therapy in the absence of concurrent disease, alternate therapy should be considered. Dogs should be monitored closely for possible adverse events associated with any increase in dose.
IMPORTANT SAFETY INFORMATION
Concurrent use of ANIPRYL with ephedrine, opioids, phenylpropanolamine, other MAO inhibitors (such as amitraz), and several classes of antidepressants is not recommended. Do not use in dogs with known hypersensitivity to the drug. In clinical studies, the most common adverse events were vomiting, diarrhea or changes in behavior, such as hyperactivity or restlessness.